Navigation Links
Cystic kidney growth curbed
Date:11/5/2012

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications. Although we have known about the disease for over a century and its genetic basis for almost 20 years, there was no effective treatment until now.

Kidneys stopped growing

"Our study highlights a potential treatment that reduces kidney growth and the associated symptoms and slows the decline in kidney function," explains Professor Olivier Devuyst from the Institute of Physiology at the University of Zurich one of the chief researchers in the phase-three clinical trial just published in the New England Journal of Medicine.

Over 1,400 patients were given tolvaptan over a three-year period at 129 centers worldwide. The drug is a selective V2 vasopressin receptor antagonist that lessens the effect of the antidiuretic (urine-concentrating) vasopressin hormone and increases urination.

The researchers studied whether tolvaptan slows the progression of the kidney disease by slowing the cyst growth. "The study achieved its goal," explains Professor Devuyst. In patients who received tolvaptan for three years instead of the placebo, the entire kidney volume decreased with fewer complications resulting from the disease, the pain eased off and the decline in kidney function was slowed. Adverse events such as increased urination and thirst as well as increased liver enzymes and blood sodium level were apparent.

15-year research project

The study is the culmination of 15 years of research done by several research groups including that of Olivier Devuyst. They began by examining transport mechanisms in cells that coat the cysts and, in particular, identified the pathway of the V2 vasopressin receptor as a potential trigger for cystic kidney disease. The demonstration that blocking this receptor slows the disease and improves the kidney function in various animal models provided the rationale for the intervention study with tolvaptan.


'/>"/>
Contact: Prof. Olivier Devuyst
olivier.devuyst@uzh.ch
41-446-355-082
University of Zurich
Source:Eurekalert

Related medicine news :

1. Cystic fibrosis patients of low SES are less likely to be accepted for lung transplant
2. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
3. Study evaluates use of inhaled saline for young children with cystic fibrosis
4. Mayo Clinic identifies promising treatment for inherited form of kidney disease
5. Eating More Fruits, Veggies May Help Kidney Patients
6. Stereotactic radiosurgery shows promise for kidney cancer
7. Obese Teens Face Higher Risk for Kidney Disease: Study
8. Abnormal carotid arteries found in children with kidney disease
9. Nearly half of kidney recipients in live donor transplant chains are minorities
10. Single-port kidney removal through the belly button boosts living-donor satisfaction
11. Kidney Stones May Be Tied to Later Kidney Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... , ... July 03, 2020 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in Charleston, ... to experts, facility features and amenities. , According to the Alzheimer’s ...
(Date:7/2/2020)... ... 2020 , ... Dr. Christine Blaine has earned a stellar reputation ... located in Staten Island, Huntington and NYC, NY. Her former Manhattan clinic, located ... at The Parlor NYC at 160 Madison Avenue. Blaine Plastic Surgery will ...
(Date:7/2/2020)... ... 2020 , ... Allegheny Health Network (AHN) today announced that John S. Lee, ... immediately. Dr. Lee succeeds Robert White, MD, who announced his plans for retirement ... year to help support a seamless transition. , Dr. Lee joins AHN from Edward-Elmhurst ...
(Date:7/1/2020)... ... July 01, 2020 , ... Dexur’s analysis of Medicare claims of ... Porter Adventist Hospital , and Sky Ridge Medical Center had the ... Dexur’s value analysis tracks a patient’s episode of care from the date of admission ...
(Date:7/1/2020)... ... 01, 2020 , ... Psilera Bioscience (“Psilera”), a ... announces its core executive team. The co-founders Drs. Jackie Salm and Chris Witowski ... as distinguished researchers within the cannabis industry. They are joined by pharmaceutical and ...
Breaking Medicine News(10 mins):
(Date:6/25/2020)... (PRWEB) , ... June 25, 2020 , ... ... on Connecticut Magazine’s 2020 Top Dentist list within the Periodontics category. As specialists, ... locations in New London, CT and Westerly, RI. Laser gum disease therapy, minimally ...
(Date:6/23/2020)... BETHESDA, Md. (PRWEB) , ... June 23, 2020 ... ... with DisasterReady.org to launch one of the first online COVID-19 trainings ... of the eight courses in this free training entitled COVID-19 Training for ...
(Date:6/23/2020)... Fla. (PRWEB) , ... June 23, 2020 , ... One ... II, Ph.D. is working to prove a similar, universal program does not work as ... coronavirus COVID-19 has affected nearly everyone’s daily life in one way or another, from ...
Breaking Medicine Technology: